Our top pick for
Building a portfolio
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
SomaLogic, a Boulder, Colorado-based biomarker discovery and clinical diagnostics company, is expected to go public via a merger with a special purpose acquisition company (SPAC). We'll update this page as new information becomes available.
SomaLogic has entered into an agreement to go public via a merger with SPAC CM Life Sciences II Inc. The SPAC is backed by activist investor Keith Meister.
SPACs, also known as a blank check company, are companies with no commercial operations that exist purely to raise capital through IPOs. No date has been announced yet.
CM Life Sciences originally went public in February 2021 and currently trades on the Nasdaq under the ticker symbol "CMIIU."
Once SomaLogic goes public, you'll need a brokerage account to invest. Consider opening a brokerage account today so you're ready as soon as the stock hits the market.
It's impossible to predict how any stock will perform — and IPOs can be particularly volatile. But evaluating the performance of companies like SomaLogic can be useful in determining how the market is performing and whether now is a good time to invest in this industry. Select a company to learn more about what they do and how their stock performs, including market capitalization, the price-to-earnings (P/E) ratio, price/earnings-to-growth (PEG) ratio and dividend yield. While this list includes a selection of the most well-known and popular stocks, it doesn't include every stock available.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Everything we know about the Talaris Therapeutics IPO, plus information on how to buy in.
Everything we know about the Sagimet Biosciences IPO, plus information on how to buy in.
Everything we know about the Zenvia IPO, plus information on how to buy in.
Everything we know about the Grove IPO, plus information on how to buy in.
Everything we know about the Pasithea Therapeutics IPO, plus information on how to buy in.
Steps to owning and managing ZTO, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZOM, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZI, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZKIN, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZION, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.